01826nas a2200361   4500000000100000008004100001260001300042653001000055653002900065653003300094653001900127653002100146653001100167653001100178653002300189653002500212653002500237653001700262653001400279653004000293653002200333653001700355100001700372700001600389700001200405700002500417700002000442245006300462300001000525490000600535520090900541022001401450       2010                            d  c2010 Jun10aAdult10aAnti-Inflammatory Agents10aDrug Administration Schedule10aDrug Eruptions10aErythema Nodosum10aFemale10aHumans10aLeprostatic Agents10aLeprosy, lepromatous10aMedication adherence10aPrednisolone10aPregnancy10aPregnancy Complications, Infectious10aTreatment Outcome10aTuberculosis1 aEickelmann M1 aSteinhoff M1 aMetze D1 aTomimori-Yamashita J1 aSunderkötter C00aErythema leprosum--after treatment of Lepromatous Leprosy.  a450-30 v83 a<p>Leprosy is usually well-controlled by multidrug therapy (MDT). However, in case of noncompliance or leprosy reactions, it may present a therapeutically challenge. A 33-year-old Brazilian woman with lepromatous leprosy was treated with MDT for one year, but then discontinued therapy because she wanted to have children. Eight weeks after stopping her medications, she developed a severe and recalcitrant erythema (nodosum) leprosum (ENL) which presented histologically with thrombosed small veins and neutrophilic inflammation in fat septa, but without arteritis. During her pregnancy and ensuing lactation period, glucocorticoids were the only suitable drug. With the use of the shortened WHO/MDT regimen (one year vs. two years of treatment), ENL will probably be seen more often after the end of leprosy therapy. It needs to be rapidly recognized and treated to avoid damage to eyes or kidneys.</p>  a1610-0387